Form 4 for EDIT Editas Medicine, Inc.
Accepted 2026-03-04 00:00:00 ET · period of report 2026-03-03 · accession 0001650664-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | 2026-03-03 | EDIT | O'Neill Gilmore Neil | CEO, Dir | S - Sale | $2.02 | -5,394 | 263.7K | -2% | -$10.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-03 | S | D | 5,394 | $2.02 | 263,693 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $2.0050 to $2.0204 The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |